Gozde Kubra Yardimci
Gozde completed her rheumatology fellowship at Hacettepe University Medical Faculty in Ankara,
and has started her VCRC-Vasculitis Foundation Fellowship. She is currently working as a clinical fellow at the Mount Sinai Hospital, University of Toronto. Her major interests are vasculitis, Pregnancy & Rheumatic diseases. Gozde is a member of the Newsletter Sub-Committee.
| Oral 0123 | Thursday 13.06.2024 10:30 AM – 12:00 Clinical Abstract Sessions: Vasculitis across different vessel sizes Author: Vieira, M (France) Title: Infliximab versus Cyclophosphamide for severe Behçet’s syndrome  The first randomized multicenter controlled trial shows induction therapy with infliximab has better complete remission rate and safer profile as compared to cyclophosphamide. |
| Poster 0207 | Thursday 13.06.2024 14:45 – 15:45 Clinical Poster Tours: Clinical aspects of small vessel vasculitis – Part 1 Author: Okazaki, A (Japan) Title: Identification of four novel clinical subtypes in patients with microscopic polyangiitis using cluster analysis: multicenter REVEAL cohort study This study attempts to identify unique subgroups with different MPA outcomes and reveals four new clinical phenotypes. |
| Poster 0077 | Thursday 13.06.2024 09:30 – 10:30 Clinical Poster Tours: Novelties in Takayasu arteritis and Giant Cell arteritis Author: López-Gutiérrez, F (Spain) Title: Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature This retrospective observational study evaluates the effectiveness of janus kinase inhibitors in relapsing giant cell arteritis. |
| Poster 0210 | Thursday 13.06.2024 14:45 – 15:45 Clinical Poster Tours: Clinical aspects of small vessel vasculitis – Part 1 Author: Klapa, S (Germany) Title: Increased risk for cardiac and vascular morbidity in ANCA-associated vasculitis (AAV): large-scale propensity-matched global retrospective cohort study Major adverse cardiovascular events and death increased in patients with ANCA-associated vasculitis (higher in MPA compared to GPA) according to a large global electronic health record database study. The AAbs profile is decisive in all patients with AD-ILD and may be linked to both expected and atypical disease characteristics. |
| Oral 0188 | Thursday 13.06.2024 10:30 AM – 12:00 Clinical Abstract Sessions: Vasculitis across different vessel sizes Author: Hellmich, B (Germany) Title: Effect of Benralizumab versus Mepolizumab on Reduction in Oral Glucocorticoid Use in Patients with Eosinophilic Granulomatosis with Polyangiitis In the Phase 3, randomised, double blind 52-week, non-inferiority head-to-head MANDARA study, treatment with either benralizumab or mepolizumab was associated with the ability to reduce oral glucocorticoids use. |